Cegolon, L.; Mastrangelo, G.; Emanuelli, E.; Camerotto, R.; Spinato, G.; Frezza, D.
Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial. Pharmaceutics 2022, 14, 2502.
https://doi.org/10.3390/pharmaceutics14112502
AMA Style
Cegolon L, Mastrangelo G, Emanuelli E, Camerotto R, Spinato G, Frezza D.
Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial. Pharmaceutics. 2022; 14(11):2502.
https://doi.org/10.3390/pharmaceutics14112502
Chicago/Turabian Style
Cegolon, Luca, Giuseppe Mastrangelo, Enzo Emanuelli, Riccardo Camerotto, Giacomo Spinato, and Daniele Frezza.
2022. "Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial" Pharmaceutics 14, no. 11: 2502.
https://doi.org/10.3390/pharmaceutics14112502
APA Style
Cegolon, L., Mastrangelo, G., Emanuelli, E., Camerotto, R., Spinato, G., & Frezza, D.
(2022). Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial. Pharmaceutics, 14(11), 2502.
https://doi.org/10.3390/pharmaceutics14112502